We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

183 hedge funds and large institutions have $975M invested in Coherus Oncology in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 59 increasing their positions, 72 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.65% less ownership

Funds ownership: 100.03% → 98.39% (-1.6%)

9% less funds holding

Funds holding: 201 → 183 (-18)

18% less repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 72

20% less capital invested

Capital invested by funds: $1.23B → $975M (-$251M)

46% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 39

98% less call options, than puts

Call options by funds: $11K | Put options by funds: $616K

Holders
183
Holders Change
-18
Holders Change %
-8.96%
% of All Funds
2.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
59
Reduced
72
Closed
39
Calls
$11K
Puts
$616K
Net Calls
-$605K
Net Calls Change
-$1.02M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$17.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.8M
3
N
Nuveen
North Carolina
+$4.11M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$3.44M
5
PCM
Peregrine Capital Management
Minnesota
+$2.62M

Top Sellers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
-$19.5M
2
RI
Redwood Investments
Massachusetts
-$11.3M
3
PA
Perceptive Advisors
New York
-$9.05M
4
Swedbank
Swedbank
Sweden
-$3.94M
5
FAM
Fred Alger Management
New York
-$3.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Principal Financial Group
26
Principal Financial Group
Iowa
$6.34M -$365K -28,666 -6%
Goldman Sachs
27
Goldman Sachs
New York
$6.13M -$1.13M -88,577 -16%
Charles Schwab
28
Charles Schwab
California
$6.04M -$98.3K -7,732 -2%
Deutsche Bank
29
Deutsche Bank
Germany
$5.37M -$57.6K -4,531 -1%
PFC
30
Phocas Financial Corp
California
$4.96M -$1.66M -130,428 -25%
Nordea Investment Management
31
Nordea Investment Management
Sweden
$4.78M +$132K +10,419 +3%
D.E. Shaw & Co
32
D.E. Shaw & Co
New York
$4.72M +$3.44M +270,122 +282%
Invesco
33
Invesco
Georgia
$4.24M +$253K +19,909 +6%
Rafferty Asset Management
34
Rafferty Asset Management
New York
$3.52M +$1.16M +90,840 +50%
Bank of America
35
Bank of America
North Carolina
$3.18M +$513K +40,380 +20%
DGI
36
Disciplined Growth Investors
Minnesota
$3.16M +$113K +8,855 +4%
EAM
37
Eagle Asset Management
Florida
$3.14M -$1.55M -121,931 -33%
CS
38
Credit Suisse
Switzerland
$2.74M +$111K +8,740 +4%
Millennium Management
39
Millennium Management
New York
$2.61M -$1.63M -128,381 -39%
Tudor Investment Corp
40
Tudor Investment Corp
Connecticut
$2.44M -$95.6K -7,521 -4%
PAM
41
Panagora Asset Management
Massachusetts
$2.43M +$119K +9,346 +5%
FAM
42
Fred Alger Management
New York
$2.29M -$3.29M -258,797 -59%
MOACM
43
Mutual of America Capital Management
New York
$2.24M +$513K +40,373 +30%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$2.13M +$114K +8,992 +6%
Renaissance Technologies
45
Renaissance Technologies
New York
$2.12M +$1.38M +108,300 +194%
BCC
46
Bridge City Capital
Oregon
$2.1M -$9.74K -766 -0.5%
Legal & General Group
47
Legal & General Group
United Kingdom
$1.98M -$21.6K -1,702 -1%
CM
48
CM Management
Florida
$1.94M +$318K +25,000 +20%
HWAM
49
Hennion & Walsh Asset Management
New Jersey
$1.89M -$66.9K -5,258 -3%
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$1.88M -$296K -23,306 -14%
1
2
3 4 5

CHRS Hedge Fund Activity: Q1 2022 in Review

183 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2022, worth a combined $975M — down 20% from $1.23B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of CHRS and 21 opened new positions — a net loss of 18 holders — while 72 trimmed existing stakes and 59 added.

The largest buyer was State Street, adding an estimated $17.1M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $19.5M sold.

  • 183 institutional investors held Coherus Oncology (CHRS) as of Q1 2022, down from 201 in Q4 2021.
  • Funds reported $975M of Coherus Oncology stock for Q1 2022, down 20% quarter-over-quarter.
  • 21 funds opened new Coherus Oncology positions in Q1 2022 and 39 closed out, a net change of -18 holders.
  • The largest Coherus Oncology buyer in Q1 2022 was State Street, an estimated $17.1M added.
  • The largest Coherus Oncology seller in Q1 2022 was Suvretta Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q1 2022.